市場調查報告書

全球肺癌治療藥市場:產業趨勢與預測

Global Lung Cancer Therapeutics Market - Industry Trends and Forecast to 2026

出版商 Data Bridge Market Research Private Limited 商品編碼 836036
出版日期 內容資訊 英文 422 Pages
商品交期: 最快1-2個工作天內
價格
全球肺癌治療藥市場:產業趨勢與預測 Global Lung Cancer Therapeutics Market - Industry Trends and Forecast to 2026
出版日期: 2019年04月01日內容資訊: 英文 422 Pages
簡介

本報告提供全球肺癌治療藥市場相關調查,彙整市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業的簡介相關資訊。

第1章 簡介

第2章 市場區隔

第3章 市場概要

  • 促進要素
  • 阻礙要素
  • 機會
  • 課題

第4章 摘要整理

第5章 高級見解

第6章 肺癌的流行病學

第7章 法律規章手續

第8章 開發平台藥物

第9章 各癌症類型市場

  • 概要
  • 非小細胞肺癌
  • 轉移性肺癌
  • 間皮瘤
  • 胸廓腫瘤
  • 肺神經內分泌腫瘤
  • 縱隔腫瘤

第10章 各分子類型市場

  • 概要
  • 低分子
  • 生技藥品

第11章 各類藥物市場

  • 概要
  • 甲醇烷基化藥
  • 代謝拮抗藥物
  • 有絲分裂抑制劑
  • 多激化酵素抑制劑
  • EGFR抑制劑
  • 其他

第12章 各治療類型市場

  • 概要
  • 放射治療
  • 化療
  • 標靶治療
  • 免疫療法
  • 其他

第13章 各療法市場

  • 概要
  • 單一藥物治療
  • 並用治療

第14章 各終端用戶市場

  • 概要
  • 醫院
  • 專門診所
  • 居家照護
  • 其他

第15章 各流通管道市場

  • 概要
  • 院內藥局
  • 零售藥局
  • 線上
  • 其他

第16章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第17章 企業趨勢

第18章 企業簡介

第19章 問題事項

第20章 相關報告

目錄

Global lung cancer therapeutics market is expected to grow at a healthy CAGR of 12.4% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation:

By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumors, Mediastinal Tumors, Mesothelioma, Chest Wall Tumors), Molecule Type (Small Molecules, Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Therapy Type (Single Drug Therapy, Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle east & Africa) Industry Trends and Forecast to 2026

Major growing sectors under the market segmentation are as follows:

  • On the basis of cancer type, the non-small cell lung cancer is dominating the global lung cancer therapeutics market. Lung cancer is the second most common cancer type including small cell and non-small cell lung cancer. Amongst these 80-85% cases are non-small cell lung cancer. This type of cancer grows and spreads more slowly than small cell lung cancer and therefore it is dominating the market.
  • On the basis of molecule type, the small molecule segment is dominating the global lung cancer therapeutics market. The small molecule better effects and progression free survival of lung cancer and these agents also inhibit the growth of the metastatic cell. Due to all these reasons they are more preferred than the other types.
  • On the drug class, the alkylating drug segment is dominating the lung cancer therapeutics market. This is the first discovered drug for the treatment of cancer. Alkylating directly damage DNA and prevents the cancer cells cell division. The alkylating agent can be used in every stage of cancer. This drug shows pre and post stage. This drug also shows reduced drug accumulation and the increased detoxification.
  • On the basis of treatment type, the chemotherapy segment is dominating the lung cancer therapeutics market. Chemotherapy is a traditional process in which drugs are used to kill or inhibit cancerous cells as it is the most accepted treatment. Whereas, targeted therapy is becoming more familiar in the lung cancer sector as these classes of drugs specifically focuses on specific genetic mutations present in the tumor cells.
  • On the basis of therapy type, single drug therapy segment is dominating the lung cancer therapeutics market. The single drug therapy is the first evolved therapy used for the treatment of lung cancer. Single drug therapy is dominating the market as it is mostly preferred for the treatment of old age population, patients with poor performance status and patients who are not able to take the combination therapy. Whereas the combination drug therapy is expected to grow in future as many combination drugs are under clinical trials and are expected to launch soon. Also, few studies have shown that combination drugs can have better results as compared to the single drug therapy which will contribute to the growth of the combination therapy in the forecast period.
  • On the basis of end user, hospitals segment is dominating the lung cancer therapeutics market. The hospital segment is dominating in the lung cancer therapeutics because hospitals provides many advantages over the other segments which includes, 24hours supportive care, immediate care for the emergency, availability of physicians, surgeons and medication.
  • On the basis of distribution channel, hospital pharmacy segment is dominating the lung cancer therapeutics market. Hospital pharmacy is dominating the global lung cancer therapeutics market as the lung cancer therapy products are prescribed based which is majorly available in hospital pharmacy.

Key Market Players:

The key market players for global lung cancer therapeutics market are listed below:

  • Takeda Pharmaceutical Company Limited
  • ONO PHARMACEUTICAL CO., LTD.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Eli Lilly and Company.
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • CELGENE CORPORATION
  • AMGEN INC.
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • ALLERGAN
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Astellas Pharma Inc.
  • Sumitomo Dainippon Pharma Co., Ltd
  • Others

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL LUNG CANCER THERAPEUTICS MARKET
  • 1.4 CURRENCY AND PRICING
  • 1.5 LIMITATIONS
  • 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 RESEARCH METHODOLOGY
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7 DBMR MARKET POSITION GRID
  • 2.8 DBMR MARKET CHALLENGE MATRIX
  • 2.9 DBMR VENDOR SHARE ANALYSIS
  • 2.10 MULTIVARIATE MODELLING
  • 2.11 PRODUCT TIME LINE
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 INCREASING CASES OF LUNG CANCER
    • 3.1.2 GROWING NUMBER OF SMOKERS
    • 3.1.3 GOVERNMENT / ORGANIZATIONS FUNDING FOR THE R&D OF NEW DRUGS
    • 3.1.4 INCREASING AWARENESS
    • 3.1.5 STRATEGIC INITIATIVES OF THE COMPANIES
  • 3.2 RESTRAINS
    • 3.2.1 PRICING PRESSURE
    • 3.2.2 HIGH COST
  • 3.3 OPPORTUNITIES
    • 3.3.1 APPROVALS AND PRODUCT PIPEPLINE
    • 3.3.2 HEALTH TOURISM
    • 3.3.3 NEW PRODUCT LAUNCHES

  • 3.4 CHALLENGES
    • 3.4.1 SIDE EFFECTS
    • 3.4.2 LACK OF NUMBER OF ONCOLOGISTS
    • 3.4.3 UNMET MEDICAL NEEDS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 EPIDEMIOLOGY OF LUNG CANCER

7 REGULATORY PROCEDURE

8 PIPELINE DRUGS

9 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE

  • 9.1 OVERVIEW
  • 9.2 NON-SMALL CELL LUNG CANCER
    • 9.2.1 SQUAMOUS CELL CARCINOMA
    • 9.2.2 PULMONARY ADENOCARCINOMA
    • 9.2.3 ADENOSQUAMOUS CARCINOMA (ASC)
    • 9.2.4 LARGE CELL CARCINOMA
    • 9.2.5 SARCOMATOID CARCINOMA
    • 9.2.6 UNDIFFERENTIATED NON-SMALL CELL LUNG CANCER
    • 9.2.7 SALIVARY GLAND-TYPE LUNG CARCINOMA
      • 9.2.7.1 ADENOID CYSTIC CARCINOMA
      • 9.2.7.2 MUCOEPIDERMOID CARCINOMA
      • 9.2.7.3 ACINIC CELL CARCINOMA
      • 9.2.7.4 EPITHELIAL-MYOEPITHELIAL CARCINOMA
      • 9.2.7.5 GRANULAR CELL LUNG TUMORS
  • 9.3 METASTATIC LUNG CANCER
  • 9.4 MESOTHELIOMA
  • 9.5 CHEST WALL TUMORS
    • 9.5.1 PRIMARY TUMORS
    • 9.5.2 METASTATIC TUMORS
    • 9.5.3 SARCOMAS
  • 9.6 PULMONARY NEUROENDOCRINE TUMORS
    • 9.6.1 CARCINOID TUMORS
      • 9.6.1.1 TYPICAL CARCINOID TUMORS
      • 9.6.1.2 ATYPICAL CARCINOID TUMORS
    • 9.6.2 LARGE CELL NEUROENDOCRINE LUNGS CARCINOMA
    • 9.6.3 SMALL-CELL LUNG CANCER
      • 9.6.3.1 SMALL CELL CARCINOMA
      • 9.6.3.2 COMBINED SMALL CELL CARCINOMA
  • 9.7 MEDIASTINAL TUMORS
    • 9.7.1 GERM CELL TUMORS
    • 9.7.2 LYMPHOMAS
    • 9.7.3 THYMOMAS

10 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE

  • 10.1 OVERVIEW
  • 10.2 SMALL MOLECULE
  • 10.3 BILOGICS

11 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS

  • 11.1 OVERVIEW
  • 11.2 ALKYLATING AGENTS
  • 11.3 ANTIMETABOLITES
  • 11.4 MITOTIC INHIBITORS
  • 11.5 MULTIKINASE INHIBITORS
  • 11.6 EGFR INHIBITORS
  • 11.7 OTHERS

12 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE

  • 12.1 OVERVIEW
  • 12.2 RADIATION THERAPY
    • 12.2.1 EXTERNAL BEAM
    • 12.2.2 BRACHYTHERAPY (INTERNAL OR IMPLANT RADIATION THERAPY)
    • 12.2.3 STEREOTACTIC BODY RADIATION THERAPY (SBRT) / STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)
    • 12.2.4 STEREOTACTIC RADIOSURGERY (SRS)
  • 12.3 CHEMOTHERAPY
    • 12.3.1 CISPLATIN
    • 12.3.2 PACLITAXEL (TAXOL)
    • 12.3.3 VINORELBINE (NAVELBINE)
    • 12.3.4 DOCETAXEL (TAXOTERE)
    • 12.3.5 ALIMTA
    • 12.3.6 GEMCITABINE (GEMZAR)
    • 12.3.7 DURVALUMAB (IMFINZI)
    • 12.3.8 OTHERS
  • 12.4 TARGETED THERAPY
    • 12.4.1 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS
    • 12.4.2 ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS
    • 12.4.3 ANTI-ANGIOGENESIS THERAPY
    • 12.4.4 MONOCLONAL ANTIBODIES
    • 12.4.5 OTHERS
  • 12.5 IMMUNOTHERAPY
    • 12.5.1 ATEZOLIZUMAB (TECENTRIQ)
    • 12.5.2 DURVALUMAB (IMFINZI)
    • 12.5.3 NIVOLUMAB (OPDIVO)
    • 12.5.4 PEMBROLIZUMAB (KEYTRUDA)
  • 12.6 OTHERS

13 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE

  • 13.1 OVERVIEW
  • 13.2 SINGLE DRUG THERAPY
  • 13.3 COMBINATION THERAPY

14 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY END USER

  • 14.1 OVERVIEW
  • 14.2 HOSPITALS
  • 14.3 SPECIALTY CLINICS
  • 14.4 HOMECARE
  • 14.5 OTHERS

15 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 15.1 OVERVIEW
  • 15.2 HOSPITAL PHARMACY
  • 15.3 RETAIL PHARMACY
  • 15.4 ONLINE
  • 15.5 OTHERS

16 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY GEOGRAPHY

  • 16.1 OVERVIEW
  • 16.2 NORTH AMERICA
    • 16.2.1 U.S.
    • 16.2.2 CANADA
    • 16.2.3 MEXICO
  • 16.3 EUROPE
    • 16.3.1 GERMANY
    • 16.3.2 FRANCE
    • 16.3.3 U.K.
    • 16.3.4 ITALY
    • 16.3.5 SPAIN
    • 16.3.6 SWITZERLAND
    • 16.3.7 NETHERLANDS
    • 16.3.8 BELGIUM
    • 16.3.9 RUSSIA
    • 16.3.10 TURKEY
    • 16.3.11 REST OF EUROPE
  • 16.4 ASIA-PACIFIC
    • 16.4.1 JAPAN
    • 16.4.2 CHINA
    • 16.4.3 INDIA
    • 16.4.4 AUSTRALIA
    • 16.4.5 SOUTH KOREA
    • 16.4.6 INDONESIA
    • 16.4.7 THAILAND
    • 16.4.8 MALAYSIA
    • 16.4.9 SINGAPORE
    • 16.4.10 PHILIPPINES
    • 16.4.11 REST OF ASIA-PACIFIC
  • 16.5 SOUTH AMERICA
    • 16.5.1 BRAZIL
    • 16.5.2 REST OF SOUTH AMERICA
  • 16.6 MIDDLE EAST AND AFRICA
    • 16.6.1 SOUTH AFRICA
    • 16.6.2 REST OF MIDDLE EAST AND AFRICA

17 GLOBAL LUNG CANCER THERAPEUTICS MARKET, COMPANY LANDSCAPE

  • 17.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 17.3 COMPANY SHARE ANALYSIS: EUROPE
  • 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

18 COMPANY PROFILES

  • 18.1 F. HOFFMANN-LA ROCHE LTD
    • 18.1.1 COMPANY SNAPSHOT
    • 18.1.2 REVENUE ANALYSIS
    • 18.1.3 GEOGRAPHICAL PRESENCE
    • 18.1.4 COMPANY SHARE ANALYSIS
    • 18.1.5 PRODUCT PORTFOLIO
    • 18.1.6 RECENT DEVELOPMENTS
  • 18.2 MERCK & CO., INC.
    • 18.2.1 COMPANY OVERVIEW
    • 18.2.2 REVENUE ANALYSIS
    • 18.2.3 GEOGRAPHICAL PRESENCE
    • 18.2.4 COMPANY SHARE ANALYSIS
    • 18.2.5 PRODUCT PORTFOLIO
    • 18.2.6 RECENT DEVELOPMENTS
  • 18.3 BRISTOL-MYERS SQUIBB COMPANY
    • 18.3.1 COMPANY OVERVIEW
    • 18.3.2 REVENUE ANALYSIS
    • 18.3.3 GEOGRAPHICAL PRESENCE
    • 18.3.4 COMPANY SHARE ANALYSIS
    • 18.3.5 PRODUCT PORTFOLIO
    • 18.3.6 RECENT DEVELOPMENTS
  • 18.4 ASTRAZENECA
    • 18.4.1 COMPANY SNAPSHOT
    • 18.4.2 REVENUE ANALYSIS
    • 18.4.3 GEOGRAPHICAL PRESENCE
    • 18.4.4 COMPANY SHARE ANALYSIS
    • 18.4.5 PRODUCT PORTFOLIO
    • 18.4.6 RECENT DEVELOPMENTS
  • 18.5 ELI LILLY AND COMPANY
    • 18.5.1 COMPANY SNAPSHOT
    • 18.5.2 REVENUE ANALYSIS
    • 18.5.3 GEOGRAPHICAL PRESENCE
    • 18.5.4 COMPANY SHARE ANALYSIS
    • 18.5.5 PRODUCT PORTFOLIO
    • 18.5.6 RECENT DEVELOPMENTS
  • 18.6 ALLERGAN
    • 18.6.1 COMPANY OVERVIEW
    • 18.6.2 REVENUE ANALYSIS
    • 18.6.3 GEOGRAPHICAL PRESENCE
    • 18.6.4 PRODUCT PORTFOLIO
    • 18.6.5 RECENT DEVELOPMENTS
  • 18.7 AMGEN INC.
    • 18.7.1 COMPANY OVERVIEW
    • 18.7.2 REVENUE ANALYSIS
    • 18.7.3 GEOGRAPHICAL PRESENCE
    • 18.7.4 PRODUCT PORTFOLIO
    • 18.7.5 RECENT DEVELOPMENTS
  • 18.8 ASTELLAS PHARMA INC.
    • 18.8.1 COMPANY OVERVIEW
    • 18.8.2 REVENUE ANALYSIS
    • 18.8.3 GEOGRAPHICAL PRESENCE
    • 18.8.4 PRODUCT PORTFOLIO
    • 18.8.5 RECENT DEVELOPMENTS
  • 18.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 18.9.1 COMPANY OVERVIEW
    • 18.9.2 REVENUE ANALYSIS
    • 18.9.3 GEOGRAPHICAL PRESENCE
    • 18.9.4 PRODUCT PORTFOLIO
    • 18.9.5 RECENT DEVELOPMENTS
  • 18.10 CELGENE CORPORATION
    • 18.10.1 COMPANY OVERVIEW
    • 18.10.2 REVENUE ANALYSIS
    • 18.10.3 GEOGRAPHICAL PRESENCE
    • 18.10.4 PRODUCT PORTFOLIO
    • 18.10.5 RECENT DEVELOPMENTS
  • 18.11 DR. REDDY'S LABORATORIES LTD.
    • 18.11.1 COMPANY SNAPSHOT
    • 18.11.2 REVENUE ANALYSIS
    • 18.11.3 GEOGRAPHICAL PRESENCE
    • 18.11.4 PRODUCT PORTFOLIO
    • 18.11.5 RECENT DEVELOPMENTS
  • 18.12 GLAXOSMITHKLINE PLC.
    • 18.12.1 COMPANY OVERVIEW
    • 18.12.2 REVENUE ANALYSIS
    • 18.12.3 GEOGRAPHICAL PRESENCE
    • 18.12.4 PRODUCT PORTFOLIO
    • 18.12.5 RECENT DEVELOPMENTS
  • 18.13 JOHNSON & JOHNSON SERVICES, INC.
    • 18.13.1 COMPANY SNAPSHOT
    • 18.13.2 REVENUE ANALYSIS
    • 18.13.3 GEOGRAPHICAL PRESENCE
    • 18.13.4 PRODUCT PORTFOLIO
    • 18.13.5 RECENT DEVELOPMENTS
  • 18.14 NOVARTIS AG
    • 18.14.1 COMPANY SNAPSHOT
    • 18.14.2 REVENUE ANALYSIS
    • 18.14.3 GEOGRAPHICAL PRESENCE
    • 18.14.4 PRODUCT PORTFOLIO
    • 18.14.5 RECENT DEVELOPMENT
  • 18.15 ONO PHARMACEUTICAL CO., LTD.
    • 18.15.1 COMPANY OVERVIEW
    • 18.15.2 REVENUE ANALYSIS
    • 18.15.3 GEOGRAPHICAL PRESENCE
    • 18.15.4 PRODUCT PORTFOLIO
    • 18.15.5 RECENT DEVELOPMENTS
  • 18.16 PFIZER INC.
    • 18.16.1 COMPANY SNAPSHOT
    • 18.16.2 RECENT FINANCIALS
    • 18.16.3 GEOGRAPHICAL PRESENCE
    • 18.16.4 PRODUCT PORTFOLIO
    • 18.16.5 RECENT DEVELOPMENTS
  • 18.17 SANOFI
    • 18.17.1 COMPANY OVERVIEW
    • 18.17.2 REVENUE ANALYSIS
    • 18.17.3 GEOGRAPHICAL PRESENCE
    • 18.17.4 PRODUCT PORTFOLIO
    • 18.17.5 RECENT DEVELOPMENTS
  • 18.18 SUMITOMO DAINIPPON PHARMA CO., LTD.
    • 18.18.1 COMPANY OVERVIEW
    • 18.18.2 REVENUE ANALYSIS
    • 18.18.3 GEOGRAPHICAL PRESENCE
    • 18.18.4 PRODUCT PORTFOLIO
    • 18.18.5 RECENT DEVELOPMENTS
  • 18.19 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 18.19.1 COMPANY SNAPSHOT
    • 18.19.2 REVENUE ANALYSIS
    • 18.19.3 GEOGRAPHICAL PRESENCE
    • 18.19.4 PRODUCT PORTFOLIO
    • 18.19.5 RECENT DEVELOPMENTS
  • 18.20 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 18.20.1 COMPANY OVERVIEW
    • 18.20.2 REVENUE ANALYSIS
    • 18.20.3 GEOGRAPHICAL PRESENCE
    • 18.20.4 PRODUCT PORTFOLIO
    • 18.20.5 RECENT DEVELOPMENTS
  • 18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 18.21.1 COMPANY OVERVIEW
    • 18.21.2 REVENUE ANALYSIS
    • 18.21.3 GEOGRAPHICAL PRESENCE
    • 18.21.4 PRODUCT PORTFOLIO
    • 18.21.5 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

LIST OF TABLES

  • TABLE 1: PREVALENCE OF SUBTYPES OF LUNG CARCINOMA IN SMOKERS AND NEVER-SMOKERS
  • TABLE 2: COST OF TARGETED THERAPIES FOR THE TREATMENT OF NSCLC (2018)
  • TABLE 3: COST OF IMMUNOTHERAPIES FOR THE TREATMENT OF NSCLC (2018)
  • TABLE 4: SOME OF THE PIPELINE LUNG CANCER DRUGS ARE MENTIONED IN THE BELOW TABLE:
  • TABLE 5: AVERAGE COST OF LUNG CANCER TREATMENT (2018)
  • TABLE 6: GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 7: GLOBAL NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 8: GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 9: GLOBAL SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 10: GLOBAL METASTATIC LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 11: GLOBAL MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 12: GLOBAL CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 13: GLOBAL CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 14: GLOBAL PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 15: GLOBAL PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 16: GLOBAL CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 17: GLOBAL SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 18: GLOBAL MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 19: GLOBAL MESOTHELIOMA IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 20: GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 21: GLOBAL SMALL MOLECULE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 22: GLOBAL BIOLOGICS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 23: GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 24: GLOBAL ALKYLATING AGENTS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 25: GLOBAL ANTIMETABOLITES IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 26: GLOBAL MITOTIC INHIBITORS PRODUCTS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 27: GLOBAL MULTIKINASE INHIBITORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 28: GLOBAL EGFR INHIBITORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 29: GLOBAL OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 30: GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 31: GLOBAL RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 32: GLOBAL RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 33: GLOBAL CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 34: GLOBAL CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 35: GLOBAL TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 36: GLOBAL TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 37: GLOBAL IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 38: GLOBAL IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 39: GLOBAL OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 40: GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 41: GLOBAL SINGLE DRUG THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 42: GLOBAL COMBINATION DRUG THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 43: GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 44: GLOBAL HOSPITALS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 45: GLOBAL SPECIALTY CLINICS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 46: GLOBAL HOMECARE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 47: GLOBAL OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 48: GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 49: GLOBAL HOSPITAL PHARMACY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 50: GLOBAL RETAIL PHARMACY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 51: GLOBAL ONLINE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 52: GLOBAL OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 54: GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017 - 2026 (USD MILLION)
  • TABLE 55: NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 56: NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 57: NORTH AMERICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 58: NORTH AMERICA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 59: NORTH AMERICA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)T
  • TABLE 60: NORTH AMERICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 61: NORTH AMERICA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 62: NORTH AMERICA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 63: NORTH AMERICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 64: NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 65: NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 66: NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 67: NORTH AMERICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 68: NORTH AMERICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 69: NORTH AMERICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 70: NORTH AMERICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 71: NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 72: NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 73: NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 74: U.S LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 75: U.S. NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 76: U.S SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 77: U.S CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 78: U.S PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 79: U.S SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 80: U.S. CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 81: U.S. MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION))
  • TABLE 82: U.S LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 83: U.S LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 84: U.S LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 85: U.S LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 86: U.S RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 87: U.S TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 88: U.S IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 89: U.S LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 90: U.S LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 91: U.S LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 92: CANADA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 93: CANADA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 94: CANADA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 95: CANADA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 96: CANADA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 97: CANADA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 98: CANADA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 99: CANADA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 100: CANADA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 101: CANADA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 102: CANADA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 103: CANADA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 104: CANADA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 105: CANADA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 106: CANADA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 107: CANADA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 108: CANADA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 109: CANADA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 110: MEXICO LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 111: MEXICO NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 112: MEXICO SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 113: MEXICO CHEST WALL TUMORS LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 114: MEXICO PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 115: MEXICO SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 116: MEXICO CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 117: MEXICO MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 118: MEXICO SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 119: MEXICO LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 120: MEXICO LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 121: MEXICO CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 122: MEXICO RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 123: MEXICO TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 124: MEXICO IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 125: MEXICO LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 126: MEXICO LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 127: MEXICO LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 128: EUROPE LUNG CANCER THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 129: EUROPE LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 130: EUROPE NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 131: EUROPE SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 132: EUROPE CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 133: EUROPE PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 134: EUROPE SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 135: EUROPE CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 136: EUROPE MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 137: EUROPE LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 138: EUROPE LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 139: EUROPE LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 140: EUROPE CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 141: EUROPE RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 142: EUROPE TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 143: EUROPE IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 144: EUROPE LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 145: EUROPE LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 146: EUROPE LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 147: GERMANY LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 148: GERMANY NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 149: GERMANY SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 150: GERMANY CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 151: GERMANY PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 152: GERMANY SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 153: GERMANY CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 154: GERMANY MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 155: GERMANY LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 156: GERMANY LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 157: GERMANY LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 158: GERMANY CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 159: GERMANY RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 160: GERMANY TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 161: GERMANY IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 162: GERMANY LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 163: GERMANY LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 164: GERMANY LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 165: FRANCE LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 166: FRANCE NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 167: FRANCE SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 168: FRANCE CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 169: FRANCE PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 170: FRANCE SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 171: FRANCE CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 172: FRANCE MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 173: FRANCE LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 174: FRANCE LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 175: FRANCE LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 176: FRANCE CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 177: FRANCE RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 178: FRANCE TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 179: FRANCE IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 180: FRANCE LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 181: FRANCE LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 182: FRANCE LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 183: U.K. LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 184: U.K. NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 185: U.K. SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 186: U.K. CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 187: U.K. PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 188: U.K. SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 189: U.K. CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 190: U.K. MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 191: U.K. LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 192: U.K. LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 193: U.K. LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 194: U.K. CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 195: U.K. RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 196: U.K. TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 197: U.K. IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 198: U.K. LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 199: U.K. LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 200: U.K. LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 201: ITALY LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 202: ITALY NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE , 2017-2026 (USD MILLION)
  • TABLE 203: ITALY SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 204: ITALY CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 205: ITALY PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 206: ITALY SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 207: ITALY CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 208: ITALY MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 209: ITALY LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 210: ITALY LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 211: ITALY LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 212: ITALY CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 213: ITALY RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 214: ITALY TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 215: ITALY IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 216: ITALY LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 217: ITALY LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 218: ITALY LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 219: SPAIN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 220: SPAIN NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 221: SPAIN SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 222: SPAIN CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 223: SPAIN PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 224: SPAIN SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 225: SPAIN CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 226: SPAIN MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 227: SPAIN LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 228: SPAIN LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 229: SPAIN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 230: SPAIN CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 231: SPAIN RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 232: SPAIN TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 233: SPAIN IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 234: SPAIN LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 235: SPAIN LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 236: SPAIN LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 237: SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 238: SWITZERLAND NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE , 2017-2026 (USD MILLION)
  • TABLE 239: SWITZERLAND SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 240: SWITZERLAND CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 241: SWITZERLAND PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 242: SWITZERLAND SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 243: SWITZERLAND CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 244: SWITZERLAND MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 245: SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 246: SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 247: SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 248: SWITZERLAND CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 249: SWITZERLAND RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 250: SWITZERLAND TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 251: SWITZERLAND IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 252: SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 253: SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 254: SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 255: NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 256: NETHERLANDS NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE , 2017-2026 (USD MILLION)
  • TABLE 257: NETHERLANDS SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 258: NETHERLANDS CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 259: NETHERLANDS PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 260: NETHERLANDS SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 261: NETHERLANDS CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 262: NETHERLANDS MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 263: NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 264: NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 265: NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 266: NETHERLANDS CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 267: NETHERLANDS RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 268: NETHERLANDS TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 269: NETHERLANDS IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 270: NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 271: NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 272: NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 273: BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 274: BELGIUM NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE , 2017-2026 (USD MILLION)
  • TABLE 275: BELGIUM SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 276: BELGIUM CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 277: BELGIUM PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 278: BELGIUM SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 279: BELGIUM CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 280: BELGIUM MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 281: BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 282: BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 283: BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 284: BELGIUM CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 285: BELGIUM RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 286: BELGIUM TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 287: BELGIUM IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 288: BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 289: BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 290: BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 291: RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 292: RUSSIA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE , 2017-2026 (USD MILLION)
  • TABLE 293: RUSSIA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 294: RUSSIA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 295: RUSSIA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 296: RUSSIA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 297: RUSSIA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 298: RUSSIA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 299: RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 300: RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 301: RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 302: RUSSIA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 303: RUSSIA RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 304: RUSSIA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 305: RUSSIA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 306: RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 307: RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 308: RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 309: TURKEY LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 310: TURKEY NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE , 2017-2026 (USD MILLION)
  • TABLE 311: TURKEY SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 312: TURKEY CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 313: TURKEY PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 314: TURKEY SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 315: TURKEY CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 316: TURKEY MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 317: TURKEY LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 318: TURKEY LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 319: TURKEY LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 320: TURKEY CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 321: TURKEY RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 322: TURKEY TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 323: TURKEY IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 324: TURKEY LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 325: TURKEY LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 326: TURKEY LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 327: REST OF EUROPE LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 328: ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 329: ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 330: ASIA-PACIFIC NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 331: ASIA-PACIFIC SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 332: ASIA-PACIFIC CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 333: ASIA-PACIFIC PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 334: ASIA-PACIFIC SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 335: ASIA-PACIFIC CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 336: ASIA-PACIFIC MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 337: ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 338: ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 339: ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 340: ASIA-PACIFIC CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 341: ASIA-PACIFIC RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 342: ASIA-PACIFIC TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 343: ASIA-PACIFIC IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 344: ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 345: ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 346: ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 347: JAPAN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 348: JAPAN NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 349: JAPAN SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 350: JAPAN CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 351: JAPAN PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 352: JAPAN SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 353: JAPAN CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 354: JAPAN MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 355: JAPAN LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 356: JAPAN LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 357: JAPAN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 358: JAPAN CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 359: JAPAN RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 360: JAPAN TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 361: JAPAN IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 362: JAPAN LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 363: JAPAN LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 364: JAPAN LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 365: CHINA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 366: CHINA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 367: CHINA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 368: CHINA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)T
  • TABLE 369: CHINA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 370: CHINA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 371: CHINA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 372: CHINA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 373: CHINA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 374: CHINA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 375: CHINA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 376: CHINA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 377: CHINA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 378: CHINA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 379: CHINA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 380: CHINA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 381: CHINA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 382: CHINA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 383: INDIA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 384: INDIA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 385: INDIA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 386: INDIA CHEST WALL TOMOURS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 387: INDIA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 388: INDIA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 389: INDIA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 390: INDIA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 391: INDIA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 392: INDIA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 393: INDIA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 394: INDIA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 395: INDIA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 396: INDIA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 397: INDIA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 398: INDIA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 399: INDIA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 400: INDIA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 401: AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 402: AUSTRALIA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 403: AUSTRALIA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 404: AUSTRALIA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 405: AUSTRALIA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 406: AUSTRALIA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 407: AUSTRALIA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 408: AUSTRALIA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 409: AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 410: AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 411: AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 412: AUSTRALIA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 413: AUSTRALIA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 414: AUSTRALIA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 415: AUSTRALIA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 416: AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 417: AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 418: AUSTRALIA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 419: SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 420: SOUTH KOREA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 421: SOUTH KOREA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 422: SOUTH KOREA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION
  • TABLE 423: SOUTH KOREA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 424: SOUTH KOREA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 425: SOUTH KOREA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 426: SOUTH KOREA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 427: SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 428: SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 429: SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 430: SOUTH KOREA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 431: SOUTH KOREA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 432: SOUTH KOREA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 433: SOUTH KOREA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 434: SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 435: SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 436: SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 437: INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 438: INDONESIA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 439: INDONESIA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 440: INDONESIA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION
  • TABLE 441: INDONESIA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 442: INDONESIA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 443: INDONESIA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 444: INDONESIA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 445: INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 446: INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 447: INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 448: INDONESIA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 449: INDONESIA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 450: INDONESIA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 451: INDONESIA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 452: INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 453: INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 454: INDONESIA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 455: THAILAND LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 456: THAILAND NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 457: THAILAND SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 458: THAILAND CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION
  • TABLE 459: THAILAND PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 460: THAILAND SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 461: THAILAND CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 462: THAILAND MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 463: THAILAND LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 464: THAILAND LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 465: THAILAND LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 466: THAILAND CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 467: THAILAND RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 468: THAILAND TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 469: THAILAND IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 470: THAILAND LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 471: THAILAND LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 472: THAILAND LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 473: MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 474: MALAYSIA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 475: MALAYSIA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 476: MALAYSIA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION
  • TABLE 477: MALAYSIA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 478: MALAYSIA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 479: MALAYSIA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 480: MALAYSIA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 481: MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 482: MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 483: MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 484: MALAYSIA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 485: MALAYSIA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 486: MALAYSIA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 487: MALAYSIA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 488: MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 489: MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 490: MALAYSIA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 491: SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 492: SINGAPORE NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 493: SINGAPORE SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 494: SINGAPORE CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION
  • TABLE 495: SINGAPORE PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 496: SINGAPORE SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 497: SINGAPORE CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 498: SINGAPORE MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 499: SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 500: SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 501: SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 502: SINGAPORE CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 503: SINGAPORE RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 504: SINGAPORE TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 505: SINGAPORE IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 506: SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 507: SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 508: SINGAPORE LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 509: PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 510: PHILIPPINES NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 511: PHILIPPINES SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 512: PHILIPPINES CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION
  • TABLE 513: PHILIPPINES PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 514: PHILIPPINES SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 515: PHILIPPINES CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 516: PHILIPPINES MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 517: PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 518: PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 519: PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 520: PHILIPPINES CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 521: PHILIPPINES RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 522: PHILIPPINES TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 523: PHILIPPINES IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 524: PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 525: PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 526: PHILIPPINES LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 527: REST OF ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 528: SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 529: SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 530: SOUTH AMERICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 531: SOUTH AMERICA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 532: SOUTH AMERICA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 533: SOUTH AMERICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 534: SOUTH AMERICA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 535: SOUTH AMERICA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 536: SOUTH AMERICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 537: SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 538: SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 539: SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 540: SOUTH AMERICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 541: SOUTH AMERICA RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 542: SOUTH AMERICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 543: SOUTH AMERICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 544: SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 545: SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 546: SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 547: BRAZIL LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 548: BRAZIL NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 549: BRAZIL SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 550: BRAZIL CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 551: BRAZIL PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 552: BRAZIL SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 553: BRAZIL CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 554: BRAZIL MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 555: BRAZIL LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 556: BRAZIL LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 557: BRAZIL LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 558: BRAZIL CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 559: BRAZIL RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 560: BRAZIL TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 561: BRAZIL IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION))
  • TABLE 562: BRAZIL LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 563: BRAZIL LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 564: BRAZIL LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 565: REST OF SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 566: MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 567: MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 568: MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 569: MIDDLE EAST & AFRICA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 570: MIDDLE EAST & AFRICA CHEST WALL TUMOR IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 571: MIDDLE EAST & AFRICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 572: MIDDLE EAST & AFRICA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 573: MIDDLE EAST & AFRICA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 574: MIDDLE EAST & AFRICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 575: MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 576: MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 577: MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 578: MIDDLE EAST & AFRICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 579: MIDDLE EAST & AFRICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 580: MIDDLE EAST & AFRICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 581: MIDDLE EAST & AFRICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 582: MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 583: MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 584: MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 585: SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 586: SOUTH AFRICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 587: SOUTH AFRICA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 588: SOUTH AFRICA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 589: SOUTH AFRICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 590: SOUTH AFRICA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 591: SOUTH AFRICA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 592: SOUTH AFRICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)
  • TABLE 593: SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION)
  • TABLE 594: SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 595: SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 596: SOUTH AFRICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 597: SOUTH AFRICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 598: SOUTH AFRICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 599: SOUTH AFRICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 600: SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION)
  • TABLE 601: SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 602: SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 603: MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL LUNG CANCER THERAPEUTICS MARKET: SEGMENTATION
  • FIGURE 2 GLOBAL LUNG CANCER THERAPEUTICS MARKET: DATA VALIDATION MODEL
  • FIGURE 3 GLOBAL LUNG CANCER THERAPEUTICS MARKET: DROC ANALYSIS
  • FIGURE 4 GLOBAL LUNG CANCER THERAPEUTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 GLOBAL LUNG CANCER THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 GLOBAL LUNG CANCER THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 GLOBAL LUNG CANCER THERAPEUTICS MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 GLOBAL LUNG CANCER THERAPEUTICS MARKET: THE MARKET CHALLENGE MATRIX
  • FIGURE 9 GLOBAL LUNG CANCER THERAPEUTICS MARKET: DBMR VENDOR SHARE ANALYSIS
  • FIGURE 10 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL LUNG CANCER THERAPEUTICS MARKET
  • FIGURE 11 COUNTRY WISE LUNG CANCER RATES IN 2018
  • FIGURE 12 GLOBAL LUNG CANCER THERAPEUTICS MARKET: SEGMENTATION
  • FIGURE 13 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE LUNG CANCER THERAPEUTICS MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2019 TO 2026
  • FIGURE 14 INCREASING CASES OF LUNG CANCER, GROWING NUMBER OF SMOKERS AND RISING GOVERNMENT INITIATIVES ARE EXPECTED TO DRIVE THE GLOBAL LUNG CANCER THERAPEUTICS MARKET IN THE FORECAST PERIOD 2019 TO 2026
  • FIGURE 15 NON-SMALL CELL LUNG CANCER IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL LUNG CANCER THERAPEUTICS MARKET IN 2019 & 2026
  • FIGURE 16 ASIA-PACIFIC IS THE MAXIMUM GROWING AND MOST PROFITABLE REVENUE POCKETS FOR GLOBAL LUNG CANCER THERAPEUTICS MARKET IN THE FORECAST PERIOD FROM 2019 TO 2026
  • FIGURE 17 WORLDWIDE LUNG CANCER INCIDENCE (2018)
  • FIGURE 18 WORLDWIDE PREVALENCE OF LUNG CANCER FOR LAST 5 YEARS
  • FIGURE 19 WORLDWIDE MORTALITY RATE OF LUNG CANCER (2018)
  • FIGURE 20 GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE, 2018
  • FIGURE 21 GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY MOLECULE TYPE, 2018
  • FIGURE 22 GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY DRUG CLASS, 2018
  • FIGURE 23 GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY TREATMENT TYPE, 2018
  • FIGURE 24 GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY THERAPY TYPE, 2018
  • FIGURE 25 GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY END USER, 2018
  • FIGURE 26 GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL, 2018
  • FIGURE 27 GLOBAL LUNG CANCER THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 28 GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY GEOGRAPHY (2018)
  • FIGURE 29 GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY GEOGRAPHY (2019 & 2026)
  • FIGURE 30 GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY GEOGRAPHY (2018 & 2026)
  • FIGURE 31 GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE (2019-2026)
  • FIGURE 32 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 33 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 34 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 35 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 36 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE (2019-2026)
  • FIGURE 37 EUROPE LUNG CANCER THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 38 EUROPE LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 39 EUROPE LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 40 EUROPE LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 41 EUROPE LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE (2019-2026)
  • FIGURE 42 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 43 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 44 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 45 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 46 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE (2019-2026)
  • FIGURE 47 SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 48 SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 49 SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 50 SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 51 SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE (2019-2026)
  • FIGURE 52 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 53 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 54 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 55 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 56 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET: BY CANCER TYPE (2019-2026)
  • FIGURE 57 GLOBAL LUNG CANCER THERAPEUTICS MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 58 NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 59 EUROPE LUNG CANCER THERAPEUTICS MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 60 ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET: COMPANY SHARE 2018 (%)